Infection with obligatory intracellular bacteria is difficult to treat, as intracellular targets and delivery methods of
therapeutics are not well known. Ehrlichia translocated factor-1 (Etf-1), a
type IV secretion system (T4SS) effector, is a primary
virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis In this study, we developed Etf-1-specific
nanobodies (Nbs) by immunizing a llama to determine if intracellular Nbs block Etf-1 functions and
Ehrlichia infection. Of 24 distinct anti-Etf-1 Nbs, NbD7 blocked mitochondrial localization of Etf-1-GFP in cotransfected cells. NbD7 and control Nb (NbD3) bound to different regions of Etf-1. Size-exclusion chromatography showed that the NbD7 and Etf-1 complex was more stable than the NbD3 and Etf-1 complex. Intracellular expression of NbD7 inhibited three activities of Etf-1 and E. chaffeensis: up-regulation of mitochondrial
manganese superoxide dismutase, reduction of intracellular
reactive oxygen species, and inhibition of cellular apoptosis. Consequently, intracellular NbD7 inhibited
Ehrlichia infection, whereas NbD3 did not. To safely and effectively deliver Nbs into the host cell cytoplasm, NbD7 was conjugated to cyclized cell-permeable
peptide 12 (CPP12-NbD7). CPP12-NbD7 effectively entered mammalian cells and abrogated the blockade of cellular apoptosis caused by E. chaffeensis and inhibited
infection by E. chaffeensis in cell culture and in a
severe combined-immunodeficiency mouse model. Our results demonstrate the development of an Nb that interferes with T4SS effector functions and intracellular pathogen
infection, along with an intracellular delivery method for this Nb. This strategy should overcome current barriers to advance mechanistic research and develop
therapies complementary or alternative to the current broad-spectrum
antibiotic.